🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Johnson & Johnson to advance Tremfya into Phase 3 for psoriatic arthritis

Published 11/07/2017, 09:01 AM
© Reuters.  Johnson & Johnson to advance Tremfya into Phase 3 for psoriatic arthritis
JNJ
-
  • Longer-term results from a Phase 2 clinical trial evaluating Johnson & Johnson's (NYSE:JNJ) TREMFYA (guselkumab) for the treatment of active psoriatic arthritis (PA) showed more that 70% of treated patients achieved at least a 20% improvement (ACR 20) in symptoms at week 56. The data were presented at the ACR/ARHP Annual Meeting in San Diego.
  • Initial results showed 58% of treated patients achieved ACR 20 at week 24 compared to 18.4% for placebo (p<0.001), the primary endpoint.
  • The company has launched two Phase 3 trials, DISCOVER-1 (patients with active PA who may have been previously treated with anti-tumor necrosis factor alpha therapies) and DISCOVER-2 (biologic therapy-naive patients).
  • Previously: FDA OKs J&J's guselkumab for plaque psoriasis (July 13)
  • Now read: Which Dividend King Rules Them All - Johnson & Johnson Or Procter & Gamble?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.